Summary
- Enterosgel treatment significantly reduced diarrhoea and pain severity leading to improved quality of life.
Abstract
Irritable Bowel Syndrome (IBS) is a psychosocial functional gastrointestinal disorder significantly reducing the patient’s quality of life. The study objective was to assess the efficiency of administration of silicon-containing enterosorbent (Enterosgel) in patients with diarrhea-predominant IBS.
30 patients with diarrhea-predominant IBS (16 women and 14 men) were included in the study. All the patients were divided into two groups: the main group was treated by enterosorbent “Enterosgel” (dosage 22.5 g 3 times a day, 1 hour after meals for 21 day), the reference group was treated with bismuth tripotassium dicitrate 1 tablet 3 times a day 30 minutes before meals and 1 tablet at night for 21 days. To assess the treatment efficiency, patients’ complaints were evaluated using GSRS questionnaire, stool frequency and form were assessed as well as myoelectric activity of the digestive tract (apparatus “Gastroenteromonitor-GEM-01”).
As a result of the treatment, patients of the main group have achieved a statistically significant reduction in the severity of abdominal pain, diarrhea syndrome, dyspepsia scales, and on the total GSRS scale. After therapy with the comparator, in patients of the reference group intensity of abdominal pain, reflux syndrome, diarrhoea syndrome and dyspepsia have significantly decreased. The most clinically significant changes observed in patients of the main group included normalized stool frequency (slowing to 7 times a week), normalization of stool form (up to type 4 on the Bristol scale) and a decrease of pain severity.
There have been no significant differences between groups in assessment of digestive tract MEA, however, the aberrant GIT response of patients with diarrhea to food intake was revealed: a decrease instead of an expected increase of MEA was noted. Thus, the study has found that application of Enterosgel reduced the complaints of patients with diarrhea-predominant IBS and abdominal pain severity, thus contributing to the harmonization of quality of patient’s life. The treatment schedule, which can be recommended for use in patients with diarrhea predominant IBS is: per os for 3 consecutive weeks at a dose of 22.5 g 3 times a day 60 minutes before meals (a dose of paste diluted in 200 ml of cool boiled water or washed down with 200 ml of cool boiled water).
